nach oben

Erschienen in:

01.10.2019 | Correction

Correction to: Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta‑Analysis

verfasst von: Jichun Yang, Shuqing Yu, Zhirong Yang, Yusong Yan, Yao Chen, Hongmei Zeng, Fei Ma, Yanxia Shi, Yehui Shi, Zilu Zhang, Feng Sun

Erschienen in: BioDrugs | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Excerpt

The authors unintentionally included in the meta-analysis both the initial abstract and the final paper of the study by Puertolas et al. [45, 48]. In order to remove this duplication, the following corrections are required. …

Titel: Correction to: Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta‑Analysis
verfasst von: Jichun Yang
Shuqing Yu
Zhirong Yang
Yusong Yan
Yao Chen
Hongmei Zeng
Fei Ma
Yanxia Shi
Yehui Shi
Zilu Zhang
Feng Sun
Publikationsdatum: 01.10.2019
Verlag: Springer International Publishing
Erschienen in: BioDrugs / Ausgabe 5/2019
Print ISSN: 1173-8804
Elektronische ISSN: 1179-190X
DOI: https://doi.org/10.1007/s40259-019-00378-x

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2019

Oncolytic Viruses: Priming Time for Cancer Immunotherapy

Author’s Reply to Puértolas-Tena and Pérez-Surio: “Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysis”

Mission Possible: Advances in MYC Therapeutic Targeting in Cancer

Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin’s Lymphoma: A Systematic Review and Meta-analysis

Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies

The Expanding Class 2 CRISPR Toolbox: Diversity, Applicability, and Targeting Drawbacks